ENDPOINTS

Two biotechs fail to beat or match Regeneron's Eylea in...

Opthea and Unity Biotechnology, which are both developing new drugs for eye dise...

Surrozen raises $175M, to focus on ophthalmology; CBC G...

Plus, news about CG Oncology, Opus Genetics and Valneva: Surrozen’s pivot an...

Novo Nordisk pays $200M upfront for United Laboratories...

Novo Nordisk is not immune to the trend of seeking obesity assets from China-bas...

Biogen plans to open new headquarters in Boston area in...

Biogen announced on Monday its plans to launch a new headquarters outside Boston...

Tempero Bio, led by ex-Novartis execs, gets $70M to red...

A small Oakland, CA-based biotech hoping to take on the sprawling landscape of s...

23andMe files for bankruptcy, CEO Wojcicki steps down

Rounding off a turbulent few years, genetic testing company 23andMe is filing fo...

Belgian biotech Augustine gets $85M for neuro and cardi...

Augustine Therapeutics has reeled in €77.7 million (about $85 million) to take o...

Teenager dies after receiving Sarepta therapy; Immunova...

Hello and welcome back to the new Endpoints Weekly. It was another busy week in ...

Liver cancer drug combo gets its second FDA rejection

The FDA has once again rejected HLB and Jiangsu Hengrui Pharmaceuticals' drug co...

Trump think tank resurrects international drug pricing ...

President Donald Trump appears poised to bring back one of the drug pricing poli...

Alnylam hopes its ATTR-CM label will give Amvuttra an edge

Alnylam will likely face challenges in turning a profit this year, despite execu...

BARDA cancels annual Industry Day

An annual gathering of industry and government officials focused on biomedical c...

The buildup to Chimerix's $935M cash exit to Jazz

Chimerix began attracting deal interest in its experimental brain tumor treatmen...

FDA approves Novartis’ Fabhalta in C3 glomerulopathy

Novartis’ Fabhalta notched another FDA approval, this time in adults with an ult...

AstraZeneca puts $2.5B toward first vaccine factory and...

AstraZeneca is again boosting its manufacturing footprint in China, this time ma...

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.